TLX News: Illuccix® Granted Transitional Pass-Through Payment Status - 31st May 2022, 9:00pm

[annb0t]

INDIANAPOLIS, May 31, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced that its prostate cancer imaging agent Illuccix® (kit for preparation of gallium Ga 68 gozetotide injection) has been granted Transitional Pass-Through Payment Status by the U.S. Centers for Medicare and Medicaid Services (CMS). (PRNewsfoto/Telix Pharmaceuticals Limited)

From 1 July 2022, CMS and commercial health insurers will recognise the Healthcare Common Procedur...

>>> Read more: Illuccix® Granted Transitional Pass-Through Payment Status